Hajo J. Flink

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

Erik H.C.J. Buster, Hajo J. Flink, Yılmaz Çakaloğlu et al. · Gastroenterology · 2008 · 394 citations · Full text

Autoimmune Disease, Hbsag Loss, Peginterferon α-2B +4

Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype

Hajo J. Flink, Monika van Zonneveld, Bettina E. Hansen et al. · The American Journal of Gastroenterology · 2006 · 260 citations

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy

Hajo J. Flink · Gut · 2005 · 115 citations · Full text

The safety of pegylated interferon alpha‐2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

Monika van Zonneveld, Hajo J. Flink, Elke Verhey et al. · Alimentary Pharmacology & Therapeutics · 2005 · 79 citations · Full text

Peg‐interferon improves liver histology in patients with HBeAg‐positive chronic hepatitis B: no additional benefit of combination with lamivudine

Monika van Zonneveld, Pieter E. Zondervan, Yılmaz Çakaloğlu et al. · Liver International · 2006 · 39 citations

Additional Benefit, Immunology, Hepatitis B +16